Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
Authors' conclusion
GLP-1 RAs at submaximal doses induce moderate, yet clinically meaningful weight loss in adults with aHO, with semaglutide showing the highest efficacy. Given the non-negligible risk of hormonal decompensation, specific endocrine monitoring is essential.
Study context
- Population
- Adults with acquired hypothalamic obesity after craniopharyngioma, 16 French obesity centres; mean age 44.4 ± 13.5 years, mean BMI 40.1 ± 8.6 kg/m², 42% T2D
- Participants
- 116 adults
- Outcome
- Weight change
- Follow-up
- Mean 44 months
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Mean weight loss
−4.6%
±12.5
Achieved ≥5% weight loss
51%
Achieved ≥10% weight loss
28%
Observational data: associations, not effects.
Further findings
| Outcome | Without diabetes | With diabetes | P value |
|---|---|---|---|
| Weight change with semaglutide by diabetes status | −8.5 ± 12.3 % | −3.9 ± 10.0 % | P = 0.032 |
Weight change with semaglutide (mean dose 1.2 mg/week)
- Semaglutide associated with the greatest reduction
- −6.8%
Safety
Endocrine adverse events
- Adrenal deficiency decompensation
- 12%
- Vasopressin deficiency decompensation
- 10%
- Requiring hospitalisation
- 8%
Gastrointestinal intolerance
- Treatment discontinuation due to GI intolerance
- 13% of cases
Original publication
Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study. Diabetes Obes Metab. Published 28 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →